Core Insights - Predictive Oncology Inc. has appointed Shawn Matthews, Thomas McLaughlin, and Sara Turken to its leadership team and Board of Directors to support its new digital asset treasury strategy focused on the Aethir (ATH) token [1][2][3] Leadership Appointments - Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, joins the Board of Directors [2][3] - Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., is appointed as Chief Investment Officer [2][4] - Sara Turken, JD, a biopharmaceutical veteran, is appointed as General Counsel [2][5] Strategic Focus - The company is leveraging its AI-driven drug discovery capabilities to implement an innovative digital treasury asset strategy, which aims to address its AI requirements and capitalize on the growing global need for AI infrastructure [3][8] - Predictive Oncology operates a digital asset treasury focused on the Aethir (ATH) token, creating the world's first Strategic Compute Reserve [8] Company Background - Predictive Oncology utilizes AI and machine learning to expedite early drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [6][7] - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [7]

Core Insights - Predictive Oncology has successfully closed two private investment in public equity transactions (PIPEs) totaling approximately $343.5 million to support its digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem [1][2] Investment Details - The PIPEs consist of two components: - A cash PIPE raising approximately $50.8 million through the sale of about 4.4 million shares of common stock at a price of $11.6265 per share [2] - A crypto PIPE involving pre-funded warrants to purchase up to approximately 14.9 million shares of common stock for a purchase price of $11.6165 per warrant, in exchange for approximately $292.7 million in notional value of ATH contributions [2] - The PIPEs closed on October 7, 2025, and the pre-funded warrants will be exercisable following shareholder approval [2][4] Strategic Intent - The company aims to utilize the in-kind contribution of ATH to fund its digital asset treasury strategy and acquire ATH in the open market, alongside working capital and general corporate purposes [4] - The investment aligns with the company's computational needs and capital requirements as it seeks to lead in AI-driven drug discovery [5] Company Background - Predictive Oncology leverages AI and machine learning for drug discovery, with its platform, PEDAL, achieving 92% accuracy in predicting tumor responses to drug compounds [9] - The company has a biobank of over 150,000 tumor samples, enhancing its AI-based drug discovery capabilities [9] Aethir Overview - Aethir is a decentralized physical infrastructure network providing GPU resources for AI computation, gaming, and cloud workloads, aiming to democratize access to AI infrastructure [7][8] - ATH serves as a utility token within the Aethir ecosystem, facilitating GPU rentals, staking, and rewards [8]

Core Viewpoint - Predictive Oncology is advancing its artificial intelligence and machine learning initiatives to enhance early drug discovery and drug development for cancer patients globally, while also implementing a digital asset treasury strategy involving ATH tokens from the Aethir ecosystem [1][14]. Transaction Overview - The company plans to raise approximately $344.4 million through two private investment transactions, which include the sale of about 66.7 million shares at a price of $0.7751 per share, generating around $51.7 million in cash proceeds, and pre-funded warrants for up to 223.6 million shares, valued at approximately $292.7 million in notional value [2]. - The transactions are expected to close around October 2, 2025, pending customary closing conditions [2]. Use of Proceeds - The funds from the private placements will primarily be used to support the digital asset treasury strategy, acquire ATH tokens in the open market, and for general corporate purposes [3]. Aethir Infrastructure - Aethir operates a large decentralized GPU network, providing AI infrastructure with cost savings of approximately 40-80% compared to traditional providers, and offers rapid deployment of services [4]. - The network consists of 435,000 GPU containers across over 200 locations in 93 countries, facilitating global access to Nvidia GPUs-as-a-Service [4]. Digital Asset Strategy - The digital asset treasury will manage ATH tokens, leveraging Aethir's model to enhance the deployment and monetization of compute resources across various enterprise sectors [5]. - For every ATH token purchased, the DCI Foundation will grant an additional 20% of the tokens to the company, linking ATH token value to real-world infrastructure demand [6]. Strategic Partnership - The partnership with Aethir is viewed as a significant opportunity for Predictive Oncology to solidify its core business and explore growth through the digital asset treasury strategy [7]. - The company aims to establish the world's first Strategic Compute Reserve, functioning as an operator within the Aethir ecosystem [8]. Advisory and Legal Support - DNA Holdings Venture, Inc. is acting as the strategic advisor for the digital asset treasury, while H.C. Wainwright & Co. serves as the exclusive placement agent for the private placements [9].

Core Viewpoint - Predictive Oncology Inc. will implement a 1-for-15 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective September 30, 2025 [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every 15 shares of common stock into one share, resulting in a reduction from 11,436,201 shares outstanding to approximately 762,414 shares [3][4]. - The reverse stock split will not change the par value per share and will affect all stockholders uniformly, with fractional shares being rounded up to the nearest whole share [3][4]. - Stockholders will receive a transaction statement from Pacific Stock Transfer, the exchange agent, detailing their new share count post-split [3][4]. Group 2: Company Overview - Predictive Oncology is focused on AI-driven drug development, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, enhancing its drug discovery capabilities [5]. - Predictive Oncology is headquartered in Pittsburgh, PA, and aims to expedite drug development for cancer patients globally [5].

Core Insights - Predictive Oncology Inc. has announced a $10 million Securities Purchase Agreement to support its strategic growth initiatives, particularly the expansion of ChemoFx in the U.S. and its launch in Europe [1][13][14] - ChemoFx is a proprietary live-cell tumor profiling assay that provides personalized chemotherapy guidance by testing multiple chemotherapies on a patient's cancer cells [2][3] - The company has a biobank of over 150,000 tumor samples, which enhances its drug response data and supports recurring revenue opportunities [3][9] ChemoFx Expansion - The groundwork for expanding ChemoFx in the U.S. is underway, with discussions ongoing with potential channel partners and pharmaceutical manufacturers [3] - Future developments of ChemoFx are expected to extend beyond gynecological cancers to include breast, colon, and lung cancers [4] High-Throughput Screening Market - The high-throughput screening market is projected to reach $69.5 billion by 2032, with a compound annual growth rate (CAGR) of 12.18%, indicating a growing adoption of 3D cell cultures for more relevant screening models [6] AI-Driven Drug Discovery - The company is advancing its AI-driven drug discovery initiatives, which include biomarker discovery and drug repurposing, leveraging its extensive biobank [8][9] - Successful collaborations, such as with UPMC Magee-Womens Hospital, have led to the development of AI-powered models that predict survival outcomes in ovarian cancer patients [10][11] Drug Repurposing Initiatives - The company has identified three drug candidates for re-evaluation in ovarian and colon cancer through active machine learning, showcasing its potential in transitioning shelved drug candidates back into clinical development [12] Funding and Financial Strategy - The Securities Purchase Agreement with Yorkville Advisors provides an efficient and flexible funding source, allowing the company to opportunistically sell shares when market conditions are favorable [13][14] - The company views this agreement as a partnership that will support its vision and growth strategy [14] Company Overview - Predictive Oncology is at the forefront of using AI and machine learning to expedite drug discovery, with a platform that predicts tumor responses with 92% accuracy [16]

Core Insights - Predictive Oncology Inc. has entered into a standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global, LP, to secure funding for its drug discovery initiatives [1][2] - The SEPA allows Predictive Oncology to sell up to $10 million worth of its stock at its discretion, with no minimum commitments or penalties for non-use [2] - The company leverages its AI-driven platform, PEDAL, which predicts drug response with 92% accuracy, enhancing drug discovery for cancer treatment [4] Funding Agreement - The SEPA provides Predictive Oncology with a flexible funding source to support ongoing drug discovery, biomarker discovery, and drug repurposing efforts [1] - Yorkville is obligated to purchase the stock, but Predictive Oncology controls the timing and amount of sales [2] - There are no associated warrants, derivatives, or other share classes with the SEPA, and it does not restrict the company's operational activities [2] Company Overview - Predictive Oncology specializes in AI and machine learning applications in drug discovery, aiming to expedite the development of cancer treatments [4] - The company has a biobank of over 150,000 tumor samples, enhancing its drug discovery capabilities [4] - Predictive Oncology is headquartered in Pittsburgh, PA, and offers one of the industry's broadest AI-based drug discovery solutions [4]

Core Viewpoint - Predictive Oncology Inc. is engaged in a legal dispute with Renovaro, Inc., with the Delaware Court of Chancery rejecting RENB's request for an expedited trial, citing delays in RENB's actions [1][2]. Company Overview - Predictive Oncology is a leader in AI-driven drug discovery, utilizing its AI platform, PEDAL, which predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds [3]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [3]. - Predictive Oncology is headquartered in Pittsburgh, PA, and operates a wholly owned CLIA laboratory facility [3]. Legal Proceedings - The court has scheduled the trial for November 12-13, 2025, and Predictive Oncology intends to defend against RENB's claims, which are deemed inaccurate and without merit [2].

Core Insights - Predictive Oncology is expanding its AI-driven drug discovery platform to include biomarker discovery and drug repurposing, positioning itself as a leader in precision oncology innovation [1][7] - The global biomarker discovery market is valued at $14.5 billion in 2024, with a projected growth rate of 19.4% CAGR through 2030, indicating significant market potential for the company [1][7] Company Developments - The company has developed AI-powered multi-omic machine learning models in collaboration with UPMC Magee-Womens Hospital, which predict survival outcomes in ovarian cancer patients, outperforming traditional clinical data models [3][4] - Predictive Oncology has identified novel ovarian cancer biomarkers linked to patient survival and drug response using advanced deep learning methods, enhancing its capabilities in biomarker discovery [6][7] - The company is actively refining its survival prediction models for integration into clinical practice at leading cancer centers worldwide, particularly for high-grade serous ovarian cancer [5][6] Drug Discovery and Repurposing - The company addresses high clinical trial failure rates in oncology by integrating real-world diversity from its biobank of 150,000 tumor samples, which enhances the Probability of Technical Success (PTS) in drug discovery [9][10] - Predictive Oncology has identified three candidates for re-evaluation in ovarian and colon cancer from previously abandoned oncology drugs, showcasing its drug repurposing capabilities [11][12] Product Expansion - The company plans to expand its flagship assay, ChemoFx®, into Europe and broaden its availability in the United States, which provides personalized treatment selection based on live-cell tumor profiling [13][14] - ChemoFx® works alongside the BioSpeciFx® molecular biomarker portfolio to help oncologists determine effective chemotherapy options for patients, initially focusing on gynecologic cancers [14] Future Outlook - The progress made in 2024 lays a strong foundation for future growth, with the company positioned to lead advancements in precision oncology through its AI innovation and proprietary data [15]

Core Insights - Predictive Oncology Inc. has made significant advancements in biomarker discovery and drug repurposing through the integration of active machine learning and a biobank of live-cell tumor specimens [1][2] - The company’s innovative approach has successfully identified three compounds for further exploration in tumor indications that have not been previously examined [3][4] Drug Discovery and Development - The efficient screening process identified Afuresertib, Alisertib, and Entinostat as promising candidates for ovarian and colon tumors, with Alisertib and Entinostat outperforming standard care drugs [4][6] - Afuresertib is an Akt inhibitor previously studied in various cancers, while Alisertib is a selective Aurora A inhibitor showing strong responses in ovarian and colon tumors [5][6] - Entinostat, an HDAC1/3 inhibitor, demonstrated strong responses in colon tumor models and is currently in clinical trials for combination therapy [7] Methodology and Future Directions - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, enhancing drug/tumor type selection for testing [10] - The next logical step involves applying this methodology to other publicly available abandoned drugs, potentially creating partnership opportunities with pharmaceutical companies [9]